SEC Filing Summary: SIGA Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
Date: July 8, 2016
Company: SIGA Technologies, Inc.
Context: The filing reports on a specific event related to the Company's Third Amended Chapter 11 Plan, confirmed by the United States Bankruptcy Court for the Southern District of New York on April 8, 2016. The event concerns the treatment of a judgment owed to PharmAthene, Inc.
Key Financial Metrics
This filing does not provide comprehensive financial statements, revenue, profit, or margin data. The only specific financial metric disclosed is a one-time payment:
- Payment to PharmAthene: $20,000,000
- Debt/Liquidity Impact: The filing does not provide updated total debt or liquidity figures, only the specific cash outflow related to the PharmAthene claim.
Material Changes and Events
On July 8, 2016, SIGA filed a Notice of Extension regarding the PharmAthene Allowed Claim Treatment Date. Key developments include:
- Notification: SIGA notified PharmAthene of its intention to satisfy the judgment under "Option 1" of the Chapter 11 Plan.
- Extension: As a consequence of the $20 million payment, the deadline for treating the PharmAthene Allowed Claim was automatically extended by 90 days to October 19, 2016.
- Payment Terms:
- If treated under Option 1: The $20 million is credited dollar-for-dollar against future payments.
- If treated under Option 3, Option 4, or Section 4.3(b)(ii): The $20 million is retained by PharmAthene and is non-refundable.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, revenue outlook, or general management commentary beyond the specific bankruptcy plan mechanics. The primary contingency is the final determination of how the PharmAthene Allowed Claim will be treated under the Plan, which dictates whether the $20 million payment is a credit or a final settlement.
Investor Verification Checklist
- Verify the final treatment option selected for the PharmAthene Allowed Claim by the October 19, 2016 deadline.
- Confirm whether the $20 million payment will be credited against future obligations or retained as a final settlement.
- Review the full text of the "Notice of Extension" (Exhibit 99.1) for detailed legal qualifications.
- Monitor subsequent filings for updates on the Company's overall liquidity position following this payment.